Acute myositis in a patient with systemic sclerosis after the administration of darbepoetin alpha.
We first describe the onset of acute myositis in a patient suffering from systemic sclerosis after the administration of darbepoetin alpha for renal failure-related anemia. Therapeutic implications and risks are discussed.
Palazzi
C
C
Division of Rheumatology, Villa Pini Clinic, Chieti, Italy. kaps57@virgilio.it
D'Agostino
L
L
D'Angelo
S
S
Petricca
A
A
Olivieri
I
I
D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000068256:Darbepoetin alfa; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007279:Injections, Subcutaneous; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009220:Myositis / Q000139:chemically induced* / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000628:therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D011241:Prednisone; D008775:Methylprednisolone